Abstract To determine whether CYP19A1 polymorphisms are associated with abnormal activity of aromatase and with musculoskeletal and bone side effects of aromatase inhibitors. DNA was isolated from tumor specimens of 4861 postmenopausal women with hormone receptor-positive breast cancer enrolled in the BIG 1-98 trial to receive tamoxifen and/or letrozole for 5 years. Tumors were genotyped for six CYP19A1 polymorphisms using PCR-based methods. Associations with breast cancer-free interval (BCFI), distant recurrence-free interval (DRFI), musculoskeletal and bone adverse events (AEs) were assessed using Cox proportional hazards models. All statistical tests were two-sided. No association between the CYP19A1 genotypes and BCFI or DRFI was observed overall. A reduced risk of a breast cancer event for tamoxifen-treated patients with rs700518 variants was observed (BCFI CC/TC vs. TT: HR 0.53, 95 % CI 0.34-0.82, interaction P = 0.08), but not observed for letrozoletreated patients. There was an increased risk of 
Introduction
The CYP19A1 gene encodes the enzyme aromatase, which is responsible for the final step in the biosynthesis of estrogens. CYP19A1 is a complex gene with many polymorphic and splice variants. Some polymorphisms have been related to abnormal activity of aromatase [1] , breast cancer risk [2] , aromatase inhibitor-associated arthralgia [3] , and bone mineral density [4] [5] [6] . Relationships between genetic variants of estrogen receptors (ERs) and their ligand, the hormone estrogen, and the enzymes that synthesize it, are not well understood. Genetically determined variants in sex steroid hormone pathways have recently been related to several measures of health status (e.g., circulating hormone concentrations, menstrual cycle profiles, lipids, diabetes mellitus, depressive symptoms, measures of cognition, bone mineral density, and vasomotor symptoms) in a community-based population of premenopausal women [7] . There is also evidence that genetic variation may explain the difference in the degree of side effects among women receiving aromatase inhibitors (AIs) for early breast cancer. Ingle et al. found that four single nucleotide polymorphisms (SNPs) (rs7158782, rs7159713, rs2369049, and rs6637820), that were closest to the T-cell leukemia 1A (TCL1A) gene, were associated with some degree of musculoskeletal symptoms using a genome-wide association case-control study [8] . In another study, a CYP19A1 SNP was associated with a decrease in bone mineral density in postmenopausal women with ER-positive breast cancer treated with AIs [9] , while in a third study, an association was found between a CYP19A1 polymorphism and AI-associated arthralgia in postmenopausal women with ER-positive breast cancer [3] .
We investigated the clinical relevance of CYP19A1 SNPs in the Breast International Group (BIG) 1-98 trial comparing adjuvant treatment with letrozole and tamoxifen, alone or in sequence, in postmenopausal women. We hypothesized that CYP19A1 genotypes that affect enzyme activity would be associated with worse disease outcomes among postmenopausal hormone receptor-positive breast cancer patients, and that the association may vary by type of endocrine therapy. We also investigated potential associations between CYP19A1 SNPs and musculoskeletal adverse events (AEs) (arthralgia and myalgia) during treatment, and bone AEs (osteoporosis and bone fractures) during and subsequent to treatment.
Methods Patients
The BIG 1-98 study [10] was a randomized, double-blind phase III trial for postmenopausal women with hormone receptor-positive early breast cancer randomly assigned to receive 5 years of tamoxifen (20 mg daily) monotherapy, 5 years of letrozole (2.5 mg daily) monotherapy, or 2 years of treatment with one agent followed by 3 years of treatment with the other, reported after median follow-up of 8.1 years [11] . BIG 1-98 enrolled 8010 women between March 1998 and May 2003. Patient visits were at baseline, every 6 months for 5 years, and yearly thereafter. Case report forms collected date of onset and severity of AEs during treatment (including bone fractures, osteoporosis, arthralgia, and myalgia) and after treatment (bone fractures and osteoporosis) using the National Cancer Institute Common Toxicity Criteria version 2.0.
Tissue collection, DNA extraction, and CYP19A1 genotyping Between 1998 and 2010, the International Breast Cancer Study Group (IBCSG) and the Danish Breast Cancer Collaborative Group carried out retrospective tissue collection in accordance with institutional guidelines and national laws. The IBCSG Biological Protocols Working Group approved this project. All material processing and genotyping were done without the knowledge of patients' treatment assignments or outcomes.
Formalin-fixed, paraffin-embedded (FFPE) primary breast cancer tissue blocks for 5786 patients were assessed for availability of invasive tumor material for translational research, as described previously [12] . In 5166 tumor blocks, an area that was representative of the invasive tumor component was identified, and one or two 1-mm cores were punched in this area. DNA was isolated for 4861 of 8010 trial patients ( Fig. 1) and was potentially available for genotyping. Genomic DNA was extracted using the QIAamp DNA FFPE tissue kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. DNA was eluted with 60 lL of sterile distilled water, quantified, and quality controlled according to the 260/280 nm ratio using the Infinite M 200 NanoQuant (Tecan, Mannedorf, Switzerland) and aliquoted at a concentration of 10 ng/lL. DNA samples were genotyped for six targeted CYP19A1 SNPs, selected based on location and/or whether they had been evaluated in prior studies: two non-synonymous SNPs, rs700519(G[A) and rs28757184(G[A); one synonymous SNP, rs700518(T[C); two SNPs in the 3 0 UTR, rs4646(C[A) and rs10046(C[T); and one intronic SNP, rs936308(C[G). All samples were processed using polymerase chain reaction (PCR)-based methods in a Clinical Laboratory Improvement Amendments (CLIA)-compliant laboratory. Two SNPs, rs4646 and rs10046, were genotyped on the 7900HT Fast Real-Time 200 PCR System (Applied Biosystems, Foster City, CA) using Taqman allele-specific assays with both providing a 95 % genotype call rate. Four SNPs were genotyped on the GenomeLab SNPstream Genotyping System (Beckman Coulter, Brea, CA). All reagents were preformulated and included in the GenomeLab SNPware Reagent kit. The GenomeLab SNPstream Genotyping System Software Suite v2.3 and SNP genotyping software (ABI) were used for array imaging and genotype calling. Optimization was performed using Applied Biosystems' TaqMan probes, in conjunction with the KlearKall Mastermix (KBioscience, Beverly, MA) or TaqMan Universal Master Mix II. For additional genotype quality assurance, sixteen samples plus four DNA controls and four no template controls were assayed in triplicate and allele calls were 100 % concordant. Comprehensive Hardy-Weinberg equilibrium testing did not reveal statistically significant violations across most sites providing tissue samples (Supplementary Table S1 ). Additionally, in order to rule out the possibility of tumorderived DNA contributing to genotype measurement errors, we compared genotypes derived from tumor versus whole blood DNA in 120 matched samples as an extension of our previous report [13] . Five of the CYP19A1 genotypes tested (rs10046, rs700518, rs700519, rs936308, and rs28757184) showed very high to complete concordance between tumors and whole blood (97.3-100 %), suggesting that tumor-derived genotypes accurately represented patients' germline genotypes.
Statistical analyses
To investigate the association of CYP19A1 genotypes with disease outcomes among endocrine therapy-treated patients, all assessable patients were included. To investigate whether the association may vary by type of endocrine therapy, analyses were limited to patients assigned to letrozole or tamoxifen monotherapy. Two disease endpoints were analyzed: (1) the breast cancer-free interval (BCFI), defined as time from randomization to first occurrence of invasive breast cancer at a local, regional, or distant site, or in the contralateral breast; and (2) the distant recurrence-free interval (DRFI), defined as time from randomization to recurrence at a distant site. In the absence of an event, the endpoints were censored at last follow-up time, or in the analyses focused on 5-year monotherapy, at time of selective crossover from tamoxifen to letrozole after dissemination of the primary trial results in 2005 [10] .
The analyses used Cox proportional hazards modeling, stratified by randomization option (2 or 4-arm) and prior chemotherapy (and by treatment assignment for analyses that included all patients). The models were also adjusted for the following characteristics at randomization: local therapy, tumor grade, tumor size, nodal status, peritumoral vascular invasion, HER2 status, and Ki-67 labeling index. The proportional hazards assumption was assessed by testing for genotype-by-time interaction and using Schoenfeld residuals.
We similarly investigated musculoskeletal and bone AEs. The endpoints were time to musculoskeletal AE, defined as time from randomization to first report of arthralgia or myalgia during protocol treatment; and time to bone AE, defined as time from randomization to first report of grade 3-4 osteoporosis or any grade bone fracture during or after protocol treatment. For musculoskeletal AEs, the Cox models were adjusted for age, body mass index (BMI), prior hormone replacement therapy use and year of randomization. For bone AEs, the models were adjusted for age, BMI, prior hormone replacement therapy use, smoking history, history of osteoporosis, bone fracture or bisphosphonate use, and for bisphosphonate use since randomization as a time-varying covariate.
Without pre-defined hypotheses, we first assessed SNP variant effects in a genotype model using logrank test and an additive model (df = 1) that compared 0 versus 1 versus Results are presented in accordance with REMARK criteria [14] . All statistical tests were two-sided. No multiple comparison adjustments were implemented, and P values \ 0.05 in the overall cohort, or interaction P values \ 0.10, were considered statistically significant.
Results
DNA tumor samples for 4861 postmenopausal patients with hormone receptor-positive breast cancer were genotyped for CYP19A1 (Fig. 1) . Patients with DNA available for genotyping were representative of the BIG 1-98 population characteristics and clinical outcomes (Table 1) . Most (98 %) patients were white, 43 % had lymph nodepositive disease, and 77 % had no previous chemotherapy. CYP19A1 genotyping was assessable for 4580 DNA samples. Characteristics of the CYP19A1 SNPs with respect to allele and genotype frequencies are shown in Supplementary Table S1 . Association between CYP19A1 genotype variants and disease outcomes
There were no associations between either BCFI or DRFI and any of the six SNPs, including the two most studied (rs4646 and rs10046), in the overall cohort of patients treated with letrozole or tamoxifen, alone or in sequence (Tables 2, S2 ). In the subset of 2653 patients assigned to a monotherapy regimen, there was a statistically significant differential treatment effect (letrozole vs. tamoxifen) for the association between BCFI and SNP rs700518(T[C) genotype variants (treatment-bygenotype interaction P = 0.08; Table 2 ; Fig. 2 ). For patients treated with tamoxifen, having the rare allele C of rs700518, either homozygous or heterozygous, was associated with a 47 % reduced hazard of a breast cancer event (HR 0.53, 95 % CI 0.34-0.82), whereas for patients treated with letrozole, the hazard of a breast cancer event was not reduced (HR 1.20, 95 % CI 0.73-1.96).
The results were consistent for DRFI (interaction P = 0.07; Table S2 ).
Association between CYP19A1 genotype variants and musculoskeletal and bone adverse events
Over the 5-year period of treatment with tamoxifen or letrozole, alone or in sequence, musculoskeletal AEs were reported for 30 % of patients. Patients with homozygous or heterozygous SNP rs700518(T[C) variants (CC or TC) were at an increased risk of reported musculoskeletal AEs (HR 1.22, 95 % CI 1.03-1.45, P = 0.02), compared with patients who had the wild-type (TT) genotype (Table 3 ; Fig. 3 ). No associations were observed for the other five SNPs, and there were no indications of differential associations between SNP variants and musculoskeletal AEs according to treatment assignment. Over the 5-year period of treatment or subsequent to treatment with tamoxifen or letrozole, alone or in sequence, bone AEs were reported for 32 % of patients. No associations between CYP19A1 genotype variants and bone AEs were observed in the cohort overall (Table 4) . Heterogeneity was observed in the association of genotype with bone AEs between treatment groups (Fig. 4) . For patients assigned to tamoxifen monotherapy, having the rare homozygous (AA), or heterozygous (CA) variant of SNP rs4646 was associated with a 24 % reduced hazard of reporting bone AEs, compared with the wild-type group (HR 0.76, 95 % CI 0.59-0.98), which was not observed for patients assigned to letrozole monotherapy (HR 1.02, 95 % CI 0.84-1.25; interaction P = 0.09). Each minor allele (C) of rs10046 was associated with a significantly increased risk of bone AEs (HR 1.28, 95 % CI 1.07-1.52) among patients assigned to tamoxifen monotherapy, which was not observed for patients assigned to letrozole but not in the letrozole group. This SNP has not been previously linked to breast cancer outcome. Interestingly, there was also an association between SNP rs700518 variants CC and TC and an increased risk of musculoskeletal AEs during endocrine therapy.
In distinct contrast, we found that three of the six CYP19A1 SNPs had statistically significant differential associations with bone AEs in patients randomized to tamoxifen versus letrozole. In the tamoxifen group, patients with the rare homozygote or heterozygote (AA/CA) variant of SNP rs4646 had a reduced risk of experiencing bone AEs, while patients with each minor allele (C) of SNP rs10046 had an increased risk of reporting a bone AE. On the other hand, patients with the rare homozygote or heterozygote (GG/GC) variant of SNP rs936308 had a reduced risk of bone AEs in the letrozole group, in contrast to an increased risk in the tamoxifen group.
Of note, we did not find any association between the three most studied SNPs, rs4646, rs10046, and rs700519, and BCFI or DRFI outcomes. In a number of studies in which these three SNPs have been investigated, conflicting results have been reported, raising the question of whether these SNPs are prognostic or predictive factors in endocrine therapy-treated breast cancer patients [15] [16] [17] [18] [19] [20] [21] . In one study, [19] only rs4646 was found to be associated with greater efficacy in 67 letrozole-treated advanced hormone receptor-positive breast cancer patients. Patients with the rs4646 SNP variant had median time to progression that was three times that of patients with the wild-type aromatase gene; but whether rs4646 was a prognostic or predictive factor could not be assessed [19] . In another study, 95 postmenopausal women with stage II-III ERpositive breast cancer were treated with neoadjuvant letrozole, and only rs4646 was associated with a poor response (P = 0.03) [17] ; progression-free survival was reduced in patients carrying (CA/AA) variants compared with those with the reference CC variant [17] . In other recent studies, rs4646 was shown to have no association with breast cancer outcome or risk [18, 20, 22] . risk of breast cancer among Hawaiian, Japanese [23] , and Korean women [24] . However, in several other reports [25] [26] [27] [28] , no association was found. Overall, in studies that were not underpowered, there were no associations found between these three SNPs and disease outcomes. Very few studies have evaluated the role that CYP19A1 SNPs play with respect to either musculoskeletal or bone AEs in postmenopausal women with endocrine-responsive breast cancer. In one study, 390 Caucasian postmenopausal women were genotyped for several SNPs and one 7 and one 8-repeat allele [3] ; 50.8 % reported having an AI-associated arthralgia and women carrying at least one 8-repeat allele had a significantly lower risk of having an AIassociated arthralgia. They also confirmed previous results [29] that women who went into menopause more recently (within 5 years) were significantly more likely to report having an AI-associated arthralgia than those greater than 10 years post menopause. Napoli et al. [9] investigated 97 postmenopausal women with ER-positive breast cancer who were treated with AIs and observed that women with the AA genotype for the CYP19A1 SNP rs700518 (G/A at Val80) developed significant bone loss at both the lumbar spine and total hip at 12 months relative to patients with GA/GG variants. We did not find any associations between bone AEs and CYP19A1 SNP rs700518 genotype variants. The reason for the discrepancy between their study and ours may be related to the small sample size in their study and the subsequently few bone AEs recorded over the study period. A recent study found that the CYP19A1 SNP rs934635 was associated with increased musculoskeletal AEs and vasomotor symptoms in patients treated with exemestane [30] . Unfortunately, we were unable to compare these results with ours because we did not test for rs934635, and it was not in linkage disequilibrium with any of the CYP19A1 SNPs examined in our cohort.
Our study has some limitations. Testing more than six additional aromatase gene SNPs might have provided additional informative variants. There may be possible sources of false-positive results, including sample size or imbalance between patient groups. Patients were from heterogeneous ethnic groups, though in general, genotype frequencies corresponded well with those reported in the literature for a predominantly European population. Nevertheless, we cannot rule out the possibility that the observed association with CYP19A1 genotypes was due to linkage disequilibrium with another causative gene and/or was the result of background genetic factors confined to an ethnically defined subgroup.
The ultimate goal of breast cancer-related pharmacogenomics studies is to use the information so patients with particular genotype variants receive the optimal therapy, either selective ER modulators (SERMs) or AIs, for the best outcome with the fewest AEs. The combination of genetic and hormonal information may help clinicians to maximize benefits, minimize AEs and determine which patients deserve close follow-up during long-term SERM or AI therapy. Our study, together with previous data, provides increasing evidence that genes involved in estrogen synthesis may modify outcomes and the risk of AEs, and enhance both quality of life and survival in women with breast cancer. Prospective investigations in larger and independent cohorts are needed to confirm these associations between CYP19A1 SNPs and breast cancer outcomes and AEs in postmenopausal endocrine-responsive breast cancer patients.
